Navigation Links
Latest Study on Stem Cell Therapy Shows Promising Signs of Recovery for Stroke Patients and Support for StemGenex® Stem Cell Therapy

La Jolla, CA (PRWEB) September 03, 2014

A new study, published on Aug. 8th, 2014 in Stem Cells Translational Medicine, has shown the positive effect stem cell therapy has had on a group of patients only 6 months after their treatment. Researchers observed significant improvements in disease-related complications in each of the 5 patients included in the study. Post-treatment brain scans of each patient revealed that stroke-related damage was reduced over time. Further, at six-month follow-ups patients demonstrated improvements in standard measures of stroke-related disability and impairment.

Researchers are being cautiously optimistic when considering these results. Similar improvements are often seen in stroke patients as part of the normal recovery process and state that more thorough studies will need to be completed. Nonetheless, the findings are absolutely astounding as the five patients included in this study suffered severe strokes. Four out of five of the patients had the most serious type of stroke. Normally only 4% of these patients survive and are able to live independently after six months of a stroke occurrence.

Clinical studies for stem cell treatment are currently being offered by StemGenex® to patients diagnosed with Stroke and other degenerative neurological diseases. Innovation is truly a driving force for StemGenex. “Stroke Patients who receive stem cell treatment through StemGenex receive multiple therapeutic modalities they simply cannot find elsewhere under one roof,” said Jeremiah McDole, Director of Scientific Research and Development at StemGenex. Offering targeted therapies that deliver stem cells past the blood brain barrier is essential to providing effective treatment for patients with neurological disorders.

StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative neurological diseases including Multiple Sclerosis, Parkinson’s Alzheimer’s disease, and others. Rita Alexander, founder of StemGenex and the company’s first stem cell patient, insists that all patients be treated like they are one of our loved ones. “Hope, compassion, and the relentless pursuit for an end to these diseases are the primary focus.”

To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Jellyfish inspires latest ocean-powered robot
2. San Diego Medical Director Wins Two Book Awards For Latest Medical Thriller
3. Texas Medical Center, the largest concentration of medical research, educational and healthcare organizations in the world, announces the first Houston Stem Cell Summit to highlight the latest stem cell research and commercialization efforts
4. Van Andel Institute Research Symposium Showcases Latest Developments In Parkinsons Research
5. Can Cannabidiol (CBD) Fight Metastatic Cancer? According to the latest research the answer is yes.
6. Karmanos Cancer Center first in Midwest to offer latest Molecular Breast Imaging
7. Cieri Media Announces New Science Series 'Bright Ideas' Focusing on Latest Inventions
8. New CfPIE Website Highlights Life Science Training Options for the Latest FDA Guidances and Standards
9. Latest Environmental Research Featured at
10. PolyScience to Exhibit Its Latest Liquid Temperature Control Solutions at Pittcon 2013
11. Douglas Harrington, MD Addresses Select Group Of Physicians Regarding Latest Advances In Cardiovascular Risk Assessment
Post Your Comments:
(Date:11/30/2015)... 2015 Partnership includes an MPP ... for the u niversity , s ... treatment s cale - up through ... Africa , where licensees based anywhere in the world will have ... --> Africa , where licensees based anywhere in the world ...
(Date:11/30/2015)... /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") today ... to its Board of Directors to replace Dr. ... wealth of experience as co-founder of Resverlogix, with expertise in ... --> --> Dr. Wong remarked, "I am ... Zenith,s long standing expertise in epigenetics and the advanced stage ...
(Date:11/30/2015)... Nov. 30, 2015  Champions Oncology, Inc. (CSBR), engaged ... to personalize the development and use of oncology drugs, ... Officer, will be presenting at the LD MICRO Investor ... Standard Time (PST).  The conference, held at the Luxe ... CA , will feature 200 small/micro-cap companies and ...
(Date:11/30/2015)... -- HUYA Bioscience International, the leader in accelerating global development ... announced it has signed a Memorandum of Understanding with ... between KDDF and HUYA with the ultimate goal of ... the global market. China,s ... preclinical and clinical stage compounds. The company advances the ...
Breaking Biology Technology:
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/9/2015)... Nov. 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... announced broader entry into the automotive market with a ... the pace of consumer electronics human interface innovation. Synaptics, ... ideal for the automotive industry and will be implemented ... Europe , Japan , ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
Breaking Biology News(10 mins):